The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
News|Articles|March 5, 2026
- Vol.27/No.5
- Volume 27
- Issue 05
Rising Incidence, Unclear Drivers: Knowledge Gaps Persist in Early-Onset CRC
Author(s)Courtney Flaherty
Fact checked by: Kyle Doherty , Kirsty Mackay
John L. Marshall, MD, and Christopher Lieu, MD, comment on the rising incidence of early-onset colorectal cancer (CRC) during CRC Awareness Month.
Advertisement
Advertisement
Colorectal cancer (CRC) incidence among adults younger than 50 years has nearly doubled since the 1990s, transforming what was once a projected trend into a present-day clinical crisis.1 By 2030, CRC is projected to increase in incidence by 90%, and recent data show that the disease is already the leading cause of cancer-related death among men and women younger than 50 years.1,2
Related to this article
Brandon Huffman, MD, discusses INCB161734’s mechanism of action, phase 1 data, and the DAWN-303 trial design in KRAS G12D–mutated pancreatic cancer.
Data from a retrospective study showed high levels of CEACAM1 expression in patients with mantle cell lymphoma.
KST-6051 received FDA fast track designation for KRAS-mutant solid tumors.
The FDA indication for adagrasib plus cetuximab for KRAS G12C–mutated locally advanced or metastatic colorectal cancer has been removed.
The FDA approved sevabertinib in first-line HER2-mutant lung cancer, durvalumab plus tarlatamab boosted survival in ES-SCLC, and more.
Read a refresh of breast cancer FDA news from August 2026, including an sNDA application in PIK3CA-mutant disease and a fast track designation.
Lanreotide injection, a generic formulation referencing lanreotide, was approved by the FDA for GEP-NETs management.
Advertisement
Advertisement